shutterstock_1940448004_hjbc

HJBC / Shutterstock.com

4 January 2022AmericasAlex Baldwin

Fed Circ rejects Sanofi’s bid to resurrect Lantus patents

The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Sanofi and C4X in $493m licensing deal

13 April 2021 UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.

GSK claims Amgen v Sanofi decision “threatens” innovation

29 April 2021 GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

More on this story

GSK claims Amgen v Sanofi decision “threatens” innovation

29 April 2021 GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

Sanofi and C4X in $493m licensing deal

13 April 2021 UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.

More on this story

GSK claims Amgen v Sanofi decision “threatens” innovation

29 April 2021 GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

Sanofi and C4X in $493m licensing deal

13 April 2021 UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.

More features

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

Trump’s return sparks calls for pro-patent agenda

EOFlow ordered to pay rival $452m over insulin patch trade secrets

Amgen faces pushback over bid to narrow patent scope